JP2018536710A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536710A5 JP2018536710A5 JP2018543283A JP2018543283A JP2018536710A5 JP 2018536710 A5 JP2018536710 A5 JP 2018536710A5 JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018543283 A JP2018543283 A JP 2018543283A JP 2018536710 A5 JP2018536710 A5 JP 2018536710A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- daily dose
- statin
- subject
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 claims 5
- 229950004781 gemcabene Drugs 0.000 claims 5
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 5
- 102000004146 ATP citrate synthases Human genes 0.000 claims 4
- 108090000662 ATP citrate synthases Proteins 0.000 claims 4
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 4
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 4
- 108010018763 Biotin carboxylase Proteins 0.000 claims 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims 4
- 230000000087 stabilizing effect Effects 0.000 claims 4
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims 3
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 3
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 3
- 229960005370 atorvastatin Drugs 0.000 claims 3
- 229960003765 fluvastatin Drugs 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 229960004844 lovastatin Drugs 0.000 claims 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 3
- 229960002797 pitavastatin Drugs 0.000 claims 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 3
- 229960002965 pravastatin Drugs 0.000 claims 3
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 3
- 229960000672 rosuvastatin Drugs 0.000 claims 3
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 3
- 229960002855 simvastatin Drugs 0.000 claims 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 201000001376 Familial Combined Hyperlipidemia Diseases 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010045263 Type IIb hyperlipidaemia Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 235000021323 fish oil Nutrition 0.000 claims 2
- 230000002440 hepatic effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 1
- 101150102415 Apob gene Proteins 0.000 claims 1
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 1
- 206010039020 Rhabdomyolysis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- -1 cholesteryl ester Chemical class 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562252147P | 2015-11-06 | 2015-11-06 | |
| US201562252195P | 2015-11-06 | 2015-11-06 | |
| US62/252,195 | 2015-11-06 | ||
| US62/252,147 | 2015-11-06 | ||
| PCT/US2016/060837 WO2017079748A1 (en) | 2015-11-06 | 2016-11-07 | Treatment of mixed dyslipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018536710A JP2018536710A (ja) | 2018-12-13 |
| JP2018536710A5 true JP2018536710A5 (OSRAM) | 2019-12-19 |
Family
ID=58663111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543079A Pending JP2018532808A (ja) | 2015-11-06 | 2016-11-07 | 心血管疾患の処置のためのゲムカベンの組み合わせ |
| JP2018543283A Pending JP2018536710A (ja) | 2015-11-06 | 2016-11-07 | 混合型脂質異常症の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543079A Pending JP2018532808A (ja) | 2015-11-06 | 2016-11-07 | 心血管疾患の処置のためのゲムカベンの組み合わせ |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9849104B2 (OSRAM) |
| EP (2) | EP3370703A4 (OSRAM) |
| JP (2) | JP2018532808A (OSRAM) |
| KR (2) | KR20180073665A (OSRAM) |
| CN (2) | CN108348491A (OSRAM) |
| AU (2) | AU2016348638A1 (OSRAM) |
| BR (2) | BR112018007857A2 (OSRAM) |
| CA (2) | CA3000016A1 (OSRAM) |
| HK (2) | HK1259458A1 (OSRAM) |
| IL (2) | IL258819A (OSRAM) |
| MA (1) | MA43190A (OSRAM) |
| MX (2) | MX2018005096A (OSRAM) |
| PH (1) | PH12018500972A1 (OSRAM) |
| RU (2) | RU2018120726A (OSRAM) |
| SG (2) | SG10201912754UA (OSRAM) |
| WO (2) | WO2017079748A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| JP6687544B2 (ja) | 2014-05-28 | 2020-04-22 | チルドレンズ ホスピタル メディカル センター | 前駆細胞を指向性分化によって胃組織に変換するための方法及びシステム |
| US11584916B2 (en) | 2014-10-17 | 2023-02-21 | Children's Hospital Medical Center | Method of making in vivo human small intestine organoids from pluripotent stem cells |
| CN107108442A (zh) | 2014-11-14 | 2017-08-29 | 燿石治疗公司 | 用于制备α,ω‑二羧酸封端的二烷醚的方法和中间体 |
| EP3370703A4 (en) * | 2015-11-06 | 2019-06-19 | Gemphire Therapeutics Inc. | GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES |
| CN109415685B (zh) | 2016-05-05 | 2023-07-04 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
| CN109689685A (zh) | 2016-07-08 | 2019-04-26 | 斯塔滕生物技术有限公司 | 抗apoc3抗体及其使用方法 |
| CN109862888B (zh) | 2016-09-28 | 2022-08-12 | 艾格尔峰生物制药有限公司 | 用于治疗非酒精性脂肪性肝炎的方法和药物组合物 |
| SG11201903697WA (en) | 2016-11-04 | 2019-05-30 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| NZ753873A (en) | 2016-12-05 | 2023-01-27 | Children’S Hospital Medical Center | Colonic organoids and methods of making and using same |
| WO2018191673A1 (en) | 2017-04-14 | 2018-10-18 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| IL269884B2 (en) * | 2017-04-18 | 2023-09-01 | Gemphire Therapeutics Inc | Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use |
| MA50958A (fr) | 2017-04-21 | 2020-10-14 | Staten Biotechnology B V | Anticorps anti-apoc3 et leurs méthodes d'utilisation |
| US20180338922A1 (en) * | 2017-05-26 | 2018-11-29 | Esperion Therapeutics, Inc. | Fixed dose formulations |
| JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
| JP2020536529A (ja) | 2017-10-10 | 2020-12-17 | チルドレンズ ホスピタル メディカル センター | 食道組織および／または臓器組成物およびそれを作製する方法 |
| US10538583B2 (en) | 2017-10-31 | 2020-01-21 | Staten Biotechnology B.V. | Anti-APOC3 antibodies and compositions thereof |
| MX2020004512A (es) | 2017-10-31 | 2020-08-13 | Anticuerpos anti apolipoproteina c-iii (anti-apoc3) y metodos de uso de los mismos. | |
| CA3082178A1 (en) * | 2017-11-28 | 2019-06-06 | Eiger Biopharmaceuticals, Inc. | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis |
| EP3727394A4 (en) | 2017-12-21 | 2021-09-08 | Children's Hospital Medical Center | DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| AU2019339410A1 (en) | 2018-09-12 | 2021-04-15 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| MX2021003156A (es) | 2018-09-18 | 2021-05-14 | 1 Globe Biomedical Co Ltd | Tratamiento para la enfermedad del higado graso no alcoholico. |
| EP3863643A4 (en) * | 2018-10-12 | 2022-07-27 | Icahn School of Medicine at Mount Sinai | Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions |
| EP3867222A4 (en) * | 2018-10-18 | 2022-07-06 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF |
| JP7610533B2 (ja) | 2019-05-31 | 2025-01-08 | チルドレンズ ホスピタル メディカル センター | 造血幹細胞の生成および拡大方法 |
| CN112851660B (zh) * | 2019-11-12 | 2022-03-18 | 广东药科大学 | 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途 |
| CN114957119B (zh) * | 2022-05-05 | 2023-06-16 | 武汉大学中南医院 | 一种四氢喹啉螺1,3-茚二酮类衍生物及其制备方法与应用 |
| WO2025186785A1 (en) * | 2024-03-08 | 2025-09-12 | TECNIMEDE - Sociedade Técnico-medicinal, SA | Oral pharmaceutical composition of pitavastatin, method and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT381664B (de) | 1984-02-07 | 1986-11-10 | Steyr Daimler Puch Ag | Einrichtung zur ueberwachung elektrischer, von einer gesteuerten wechselstromquelle gespeister widerstandsschweissvorgaenge, insbesondere punktschweissungen |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| CA2039763A1 (en) | 1990-04-30 | 1991-10-31 | Henry Y. Pan | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| HUP9601808A3 (en) | 1995-07-03 | 2000-06-28 | Sankyo Co | Treatment of arteriosclerosis and xanthoma |
| AU7478496A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine antagonists |
| AU7669496A (en) | 1995-11-03 | 1997-05-22 | University Of Kentucky | Method for the intranasal administration of l-dopa prodrugs |
| ATE451926T1 (de) * | 1997-07-31 | 2010-01-15 | Abbott Respiratory Llc | Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie |
| US20030105154A1 (en) * | 2001-10-24 | 2003-06-05 | Bisgaier Charles Larry | Statin-carboxyalkylether combinations |
| NZ503982A (en) | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| US6861555B2 (en) | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| EP1494665A1 (en) * | 2002-03-29 | 2005-01-12 | The Board of Trustees of The Leland Stanford Junior University | Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| WO2004045596A1 (en) * | 2002-11-15 | 2004-06-03 | Warner-Lambert Company Llc | Method of lowering crp and reducing systemic inflammation |
| US20040229954A1 (en) * | 2003-05-16 | 2004-11-18 | Macdougall Diane Elaine | Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt |
| JP2006131559A (ja) * | 2004-11-05 | 2006-05-25 | Takeda Chem Ind Ltd | 含窒素複素環化合物 |
| WO2006054308A2 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| CA2600429A1 (en) * | 2005-03-08 | 2006-09-14 | Reliant Pharmaceuticals, Inc. | Treatment with statin and omega-3 fatty acids and a combination product thereof |
| WO2006102674A2 (en) * | 2005-03-24 | 2006-09-28 | Microbia, Inc. | Diphenylheterocycle cholesterol absorption inhibitors |
| US20090297496A1 (en) * | 2005-09-08 | 2009-12-03 | Childrens Hospital Medical Center | Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| AU2006331770A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist |
| US9561188B2 (en) * | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
| AU2007281212B8 (en) | 2006-08-03 | 2013-02-28 | Trustees Of Tufts College | Non-flushing niacin analogues, and methods of use thereof |
| WO2008023869A1 (en) * | 2006-08-24 | 2008-02-28 | Hanall Pharmaceutical Co., Ltd. | Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| FI20080353A0 (fi) * | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi |
| WO2008091863A1 (en) | 2007-01-23 | 2008-07-31 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| US20100144864A1 (en) * | 2007-04-05 | 2010-06-10 | Ironwood Pharmaceuticals, Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US9307371B2 (en) | 2008-01-18 | 2016-04-05 | Verizon Patent And Licensing Inc. | Method and system for SMS/MMS messaging to a connected device |
| NZ589469A (en) * | 2008-05-20 | 2012-08-31 | Cerenis Therapeutics Holding S A | Niacin and NSAID combination for reducing niacin-induced flushing |
| US20110082119A1 (en) * | 2008-06-13 | 2011-04-07 | Takashi Yano | Prophylactic/ameliorating or therapeutic agent for non-alcoholic steatohepatitis |
| EP2488180A4 (en) | 2009-10-12 | 2013-03-27 | Ipca Lab Ltd | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT / PROPHYLAXIS OF NON ALCOHOLIC HEPATIC STEATOSIS |
| ES2677969T3 (es) * | 2010-01-08 | 2018-08-07 | Ionis Pharmaceuticals, Inc. | Modulación de la expresión tipo angiopoyetina 3 |
| WO2011163612A1 (en) * | 2010-06-24 | 2011-12-29 | Trustees Of Tufts College | Niacin mimetics, and methods of use thereof |
| TR201005325A2 (tr) * | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
| CA2822921C (en) * | 2010-12-27 | 2018-07-17 | Charles L. Bisgaier | Gemcabene and derivatives thereof for treating or preventing pancreatitis |
| EP2604256B1 (en) * | 2011-12-14 | 2016-04-13 | Hexal AG | Multi layer coatings |
| CN102525942A (zh) * | 2012-01-05 | 2012-07-04 | 金陵药业股份有限公司 | 一种阿托伐他汀钙肠溶微丸及其制备方法 |
| MX367352B (es) * | 2012-01-06 | 2019-08-16 | Gemphire Therapeutics Inc | Metodos para reducir el riesgo de padecer una enfermedad cardiovascular. |
| WO2015143276A1 (en) * | 2014-03-20 | 2015-09-24 | Esperion Therapeutics, Inc. | Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders |
| CN104127391B (zh) * | 2014-08-05 | 2016-08-24 | 李宝齐 | 一种含有阿托伐他汀钙的固体药物组合物 |
| EP3370703A4 (en) * | 2015-11-06 | 2019-06-19 | Gemphire Therapeutics Inc. | GEMCABEN COMBINATIONS FOR TREATING HEART CIRCULATION DISEASES |
| CN105434391A (zh) * | 2016-01-18 | 2016-03-30 | 上海蓝心医药科技有限公司 | 阿托伐他汀钙肠溶片及其制备方法和应用 |
-
2016
- 2016-11-07 EP EP16863175.2A patent/EP3370703A4/en not_active Withdrawn
- 2016-11-07 HK HK19101864.0A patent/HK1259458A1/zh unknown
- 2016-11-07 CN CN201680064197.2A patent/CN108348491A/zh active Pending
- 2016-11-07 JP JP2018543079A patent/JP2018532808A/ja active Pending
- 2016-11-07 MA MA043190A patent/MA43190A/fr unknown
- 2016-11-07 CN CN201680064715.0A patent/CN108366957A/zh active Pending
- 2016-11-07 HK HK19100291.5A patent/HK1257929A1/zh unknown
- 2016-11-07 CA CA3000016A patent/CA3000016A1/en not_active Abandoned
- 2016-11-07 KR KR1020187014906A patent/KR20180073665A/ko not_active Withdrawn
- 2016-11-07 MX MX2018005096A patent/MX2018005096A/es unknown
- 2016-11-07 JP JP2018543283A patent/JP2018536710A/ja active Pending
- 2016-11-07 WO PCT/US2016/060837 patent/WO2017079748A1/en not_active Ceased
- 2016-11-07 EP EP16863170.3A patent/EP3370713A4/en not_active Withdrawn
- 2016-11-07 SG SG10201912754UA patent/SG10201912754UA/en unknown
- 2016-11-07 KR KR1020187013334A patent/KR20180073597A/ko not_active Withdrawn
- 2016-11-07 BR BR112018007857A patent/BR112018007857A2/pt not_active Application Discontinuation
- 2016-11-07 RU RU2018120726A patent/RU2018120726A/ru not_active Application Discontinuation
- 2016-11-07 WO PCT/US2016/060849 patent/WO2017079755A1/en not_active Ceased
- 2016-11-07 AU AU2016348638A patent/AU2016348638A1/en not_active Abandoned
- 2016-11-07 SG SG11201803442UA patent/SG11201803442UA/en unknown
- 2016-11-07 BR BR112018009238A patent/BR112018009238A8/pt not_active Application Discontinuation
- 2016-11-07 MX MX2018005540A patent/MX2018005540A/es unknown
- 2016-11-07 CA CA3001627A patent/CA3001627A1/en not_active Abandoned
- 2016-11-07 AU AU2016349634A patent/AU2016349634A1/en not_active Abandoned
- 2016-11-07 RU RU2018120599A patent/RU2018120599A/ru not_active Application Discontinuation
-
2017
- 2017-01-26 US US15/416,911 patent/US9849104B2/en active Active
- 2017-02-03 US US15/424,620 patent/US20170172955A1/en not_active Abandoned
- 2017-11-16 US US15/814,557 patent/US10449154B2/en active Active
-
2018
- 2018-04-22 IL IL258819A patent/IL258819A/en unknown
- 2018-05-04 US US15/971,491 patent/US20180325825A1/en not_active Abandoned
- 2018-05-04 IL IL259133A patent/IL259133A/en unknown
- 2018-05-04 PH PH12018500972A patent/PH12018500972A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536710A5 (OSRAM) | ||
| RU2018120599A (ru) | Лечение смешанной дислипидемии | |
| JP6295205B2 (ja) | 心血管疾患のリスクを低減する方法 | |
| JP2022116083A5 (OSRAM) | ||
| JP2015503588A5 (OSRAM) | ||
| Mani et al. | Niacin therapy, HDL cholesterol, and cardiovascular disease: is the HDL hypothesis defunct? | |
| FI3911648T3 (fi) | 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön | |
| JP2016538248A5 (OSRAM) | ||
| JP2012097105A5 (OSRAM) | ||
| RU2017136295A (ru) | Фиксированные комбинации и составы, содержащие етс1002 и один или более статинов, и способы лечения или уменьшения риска развития сердечно-сосудистого заболевания | |
| EP3035934A2 (en) | Compositions and therapeutic methods for accelerated plaque regression | |
| JP2012505905A5 (OSRAM) | ||
| JP2017519028A5 (OSRAM) | ||
| Salakhutdinov et al. | Triglyceride-lowering agents | |
| JP2007527433A5 (OSRAM) | ||
| US7776354B2 (en) | Remedies for glomerular diseases | |
| JP2020535142A5 (OSRAM) | ||
| JP2019533705A5 (OSRAM) | ||
| JP2018027953A (ja) | 膵炎を治療するためのゲムカベンおよび誘導体 | |
| RU2007149337A (ru) | Новый способ лечения гиперлипидемии | |
| JP2014509305A5 (OSRAM) | ||
| KR20230142523A (ko) | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 | |
| Park et al. | KOREAN ROSUVASTATIN EFFECTIVENESS STUDY IN NONDIABETIC METABOLIC SYNDROME (KREST) | |
| Chapman | Current drug information: Excess cardiovascular risk in inflammatory rheumatic diseases | |
| Paragh et al. | ANIMAL MODEL FOR SIMULTANEOUS STUDY OF STATIN-EFFECTS AGAINST HYPERCHOLESTEROLEMIA AND TUMOR DEVELOPMENT |